Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Breyanzi is a prescription CD19-directed genetically modified autologous T-cell immunotherapy containing lisocabtagene maraleucel. It is made from a patient's own T cells and is used for selected relapsed or refractory B-cell cancers in adults. Current indications include large B-cell lymphoma, chronic lymphocytic leukemia or small lymphocytic lymphoma, follicular lymphoma, mantle cell lymphoma, and marginal zone lymphoma.
read more about breyanzi ...Breyanzi T cells are genetically modified to express a chimeric antigen receptor that recognizes CD19 on B-lineage cells. Binding to CD19 activates the modified T cells, leading to proliferation, cytokine release, and destruction of CD19-positive cells. The treatment contains separate CD8-positive and CD4-positive CAR T-cell components.
Breyanzi is approved for selected adults with large B-cell lymphoma and for relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, follicular lymphoma, mantle cell lymphoma, and marginal zone lymphoma after specified prior therapies. It is not indicated for central nervous system lymphoma.
Breyanzi is given once by intravenous infusion after lymphodepleting chemotherapy with fludarabine and cyclophosphamide. Most listed indications use 90 million to 110 million CAR-positive viable T cells. Large B-cell lymphoma after two or more prior therapy lines uses 50 million to 110 million cells. Acetaminophen and an H1 antihistamine are given before infusion.
Breyanzi carries boxed warnings for cytokine release syndrome, neurologic toxicities, and secondary hematologic malignancies. Other risks include serious infections, prolonged low blood cell counts, low immunoglobulin levels, hypersensitivity, and an immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome. Patients are monitored closely after infusion for fever, neurologic changes, and other toxicities.
Yes. Breyanzi is an autologous CD19-directed CAR T-cell therapy made from the patient's own T cells.
Breyanzi is administered as a single treatment infusion after lymphodepleting chemotherapy.
Current indications include selected large B-cell lymphoma, chronic lymphocytic leukemia or small lymphocytic lymphoma, follicular lymphoma, mantle cell lymphoma, and marginal zone lymphoma.
Yes. Boxed warnings cover cytokine release syndrome, neurologic toxicities, and secondary hematologic malignancies.
BREYANZI (lisocabtagene maraleucel) Prescribing Information. https://packageinserts.bms.com/pi/pi_breyanzi.pdf. Date Accessed September 16, 2026.
BREYANZI (lisocabtagene maraleucel). U.S. Food and Drug Administration. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/breyanzi-lisocabtagene-maraleucel. Date Accessed September 16, 2026.
DailyMed - BREYANZI (lisocabtagene maraleucel) kit. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=594bb413-af3b-4b97-afb3-bfe2b174f2ed. Date Accessed September 16, 2026.
FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lisocabtagene-maraleucel-relapsed-or-refractory-marginal-zone-lymphoma. Date Accessed September 16, 2026.
Lisocabtagene Maraleucel. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/drugs/lisocabtagenemaraleucel. Date Accessed September 16, 2026.